Trial Profile

Evaluation of p53peptide-pulsed Dendritic Cells in Combination With an Aromatase Inhibitor as a Treatment for Patients With Breast Cancer With Disease Recurrence After Adjuvant or First Line Endocrine Therapy.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary) ; Cancer vaccine-p53 (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Interleukin-2; Thymalfasin
Indications Advanced breast cancer
Focus Therapeutic Use

07 Jul 2012 SciClone Pharmaceuticals added as associations as reported in the European Clinical Trials Database record.
30 May 2012 Planned end date changed from 1 Jul 2013 to 1 May 2012 as reported by ClinicalTrials.gov.
30 May 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com